stem cells

Andreas Zeiher in conversation with Ulf Landmesser: Stem cells - An Update

On March 9, 2009, President Barack Obama signed an executive order to lift a ban on federal funding for embryonic stem cell research that had been in place since August, 2001. In this video, Susan Fisher, director of the UCSF Human Embryonic Stem Cell Center, and Alan Trounson, president of the California Institute for Regenerative Medicine, discuss how the federal ban affected stem cell researchers and how President Obama's stem cell research policies will bring new opportunities in this field.

In 2006 scientists learned how to create a pluripotent stem cell out of a human skin cell. These cells, called induced pluripotent stem (iPS) cells have many of the characteristics of embryonic stem cells including the ability to create mature cell types. Dr. Jerome Zack has a CIRM grant to create iPS cells that could be used in human therapies. Zack is Associate Director, UCLA AIDS Institute, professor of Medicine, Microbiology, Immunology & Molecular Genetics, and a scientist with the Eli...

Embryonic stem cells have the potential to help treat 70 or more diseases, but developing those new therapies will take time. Alan Lewis is president and CEO of Novocell, a La Jolla-based company that has been developing a potential therapy for diabetes. Novocell has a CIRM grant to assemble a team of researchers who will accelerate the time it takes to get that potential therapy to the FDA for clinical trials.

A major challenge in developing stem cell-based cures for disease is maturing those cells into adult cell types that can be used for transplantation or to study human disease. Mark Mercola has a CIRM grant to derive heart muscle cells from embryonic stem cells. In this video, Dr. Mercola describes how stem cells could one day be used for transplantation, for testing new drugs for side effects on heart muscle cells, and to learn about how the heart cells mature and develop. That knowledge...

Stem cells have both the capacity to self-renew, that is, to divide and create additional stem cells, and also to differentiate along a specified molecular pathway. Embryonic stem cells are very nearly totipotent, reserving the elite privileges of choosing among most if not all of the differentiation pathways that specify the animal. In contrast, stem cells that reside within an adult organ or tissue have more restricted options, often able to select a differentiation program from only a few...

Dr. Leonard Zon is internationally recognized for his pioneering work in the fields of stem cell biology and cancer genetics. He received his MD from Jefferson Medical College, Philadelphia. He is founder and former president of the International Society for Stem Cell Research and chair of the Executive Committee of the newly formed Harvard Stem Cell Institute (HSCI). In 2005, Dr. Zon was elected to the Institute of Medicine of the National Academies. He recently completed a term as President...

Richard Young’s research combines novel high-throughput biological methods with new computational techniques to investigate the mechanisms that control genes in living cells. Recent results from his group include the discovery of the core regulatory circuitry of human embryonic stem cells and insights into the mechanisms that control human development. Dr. Young believes that knowledge of regulatory circuitry will provide the foundation for future therapeutic strategies against major human...

Dr. Max S. Wicha is the founding Director of the University of Michigan Comprehensive Cancer Center and distinguished professor of oncology. His lab was part of the team that first discovered stem cells in breast cancer, the first described in any human solid tumor. He is a leading expert in normal and malignant breast stem cells. Dr. Wicha is also active as a clinician, specializing in the treatment of breast cancer.

Irving L. Weissman, M.D., is the Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine, Director of the Stanford Cancer Center and Director of the Stanford Ludwig Center for Stem Cell Research. Dr. Weissman was a member of the founding Scientific Advisory Boards of Amgen (1981-1989), DNAX (1981-1992), and T-Cell Sciences (1988-1992). He co-founded SyStemix in 1988, StemCells in 1996, and Celtrans (now Cellerant), the successor to SyStemix, in 2001. He is a...